[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"atrium-fibrillation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:atrium-fibrillation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100528802","convergent-ablation-plus-left-atrial-appendage-isolation-for-the-treatment-of-persistent-atrial-fibrillation-100528802",false,"NCT06165510","Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation","CLIP-AF","Inclusion Criteria:\n\n* Age \\> 18 years; \\\u003C 80 years\n* Persistent AF \\> 1-year duration\n* Left atrium size \\\u003C 6cm\n* Pts should be able to provide written informed consent.\n\nExclusion Criteria:\n\n* Subjects currently enrolled in another investigational study except in case of observational registry with no associated treatments.\n* Subject has a reversible cause of AF or transient AF\n* Subject is absent of LAA or if the LAA is previously surgically ligated\n* Subject has had previous cardiac surgery or abdominal surgery.\n* Subject has contraindication to anticoagulation.\n* Patients with hypertrophic cardiomyopathy.\n* Patients with significant valve disease.\n* Subject has had previous catheter or surgical ablation",true,"ALL","18 Years","80 Years",{"count":21,"type":22},48,"ESTIMATED","INTERVENTIONAL",[25],"NA","A randomised controlled clinical trial to assess efficacy of convergent ablation with the LARIAT procedure, as compared to standard endocardial catheter ablation in patients with long-standing persistent atrial fibrillation (AF).",[28,29,30,31],"Persistent Atrial Fibrillation","Atrial Fibrillation, Persistent","Atrium; Fibrillation","Atrial Arrhythmia",[33,34,35,36,37],"Catheter ablation","Convergent procedure","Left atrial appendage","Hybrid ablation","Cardiac arrhythmias","RECRUITING","2026-06-24",{"date":41,"type":42},"2026-06-25","ACTUAL",{"date":44,"type":42},"2024-08-02",{"date":46,"type":22},"2026-11",{"name":48,"class":49},"Barts & The London NHS Trust","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":62,"conditions":63,"keywords":64,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100487915","personalised-ablation-strategies-in-af-100487915","NCT05633303","Personalised Ablation Strategies in AF","Developing Dynamic Substrate Targeted Personalised Treatment Strategies in AF.","PAS","Inclusion Criteria:\n\n* Patients undergoing catheter ablation for persistent AF (\\\u003C24 months AF duration and no previous left atrial ablation).\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Unwillingness to sign consent\n* Age \\\u003C18 years\n* Contraindications for catheter ablation procedure",{"count":60,"type":22},160,[25],"Atrial fibrillation (AF) is the most common arrhythmia with an expected rise in prevalence over the next decade. Catheter ablation is a safe treatment option in eliminating AF however, success rates still remains variable. Existing strategies do not take into account the differences in AF perpetuation mechanisms beyond the pulmonary veins (PVs) due to the underlying substrate. Here, I will investigate the differences in persistent AF mechanisms due to the underlying substrate and utilise these findings to generate AF mechanism specific ablation strategies. I have defined a new metric, rate-dependent conduction velocity (RDCV) slowing that has shown to correlate with sites of re-entry activity in AF. In this study, techniques and methods will be developed to measure RDCV slowing sites. The impact autonomic modulation has on AF mechanisms and CV dynamics will also be assessed. The hypothesis is that a combination of structural, electrical and autonomic remodelling play an important mechanistic role in persistent AF and ablation strategies adapted to target these will result in greater procedural success rate. The study findings have the potential to improve the success rate of catheter ablation in persistent AF thereby improve patient wellbeing and reduce the cost burden of AF treatment.",[30],[65,66,67,68],"Atrial fibrillation","Autonomic remodelling","Conduction velocity","Novel ablation strategies","2026-05-05",{"date":71,"type":42},"2026-05-08",{"date":73,"type":42},"2022-10-14",{"date":75,"type":22},"2027-10-10",{"name":48,"class":49},{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":106},"100547044","phase-4-vitamin-k-antagonist-factor-xa-inhibitor-or-no-anticoagulation-in-atrial-fibrillation-and-dialytic-end-stage-renal-disease-visionaire-100547044","NCT06402851","Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)","A Randomized Clinical Trial Comparing Three Anti-Thrombotic Strategies for Patients with Atrial Fibrillation and Severe Chronic Kidney Dysfunction","VISIONAIRE","Inclusion Criteria:\n\n* Patients with clinical atrial fibrillation or flutter (persistent, paroxysmal or permanent);\n* CHA2DS2-Vasc ≥ 2 points (≥ 3 if female);\n* Chronic kidney disease with estimated glomerular filtration rate (eGFR) ≤ 15 ml\u002Fmin\u002F1.73 m2 by the CKD-EPI equation (confirmed by two lab results at least 3 months apart) or on chronic renal replacement therapy (Of note: number of patients included in no renal replacement therapy stratum will be capped at around 30% from the total study population).\n\nExclusion Criteria:\n\n* Active bleeding or severe bleeding \\\u003C 1 month;\n* Prior kidney transplantation;\n* Refusal de provide consent\n* Severe chronic liver disease (Child C);\n* Other indication of oral anticoagulation (e.g.,: venous thromboembolism or pulmonary embolism);\n* Prior intracranial hemorrhage;\n* Bleeding disorder (other than uremia);\n* Platelet count \\\u003C 50,000 \u002F mm3 ;\n* Pregnancy or breastfeeding;\n* Mechanical valvar prosthesis;\n* Moderate to severe mitral stenosis;\n* Need for antithrombotic drugs other than single antiplatelet agents, or need for dual antiplatelet therapy with aspirin plus an ADP receptor blocker;\n* Any comorbidity beyond CKD and CV disease (e.g., metastatic cancer) which, in the investigator´s opinion, may impact survival in 12 months.",{"count":86,"type":22},1500,[88],"PHASE4","VISIONAIRE (Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE) trial will be a prospective randomized open-label with blinded endpoint adjudication trial including 1500 patients with atrial fibrillation or atrial flutter and advanced chronic kidney disease",[30,91],"Chronic Kidney Diseases",[93,94,95,96],"atrial fibrillation","atrial flutter","oral anticoagulation","dialysis","2025-02-19",{"date":99,"type":42},"2025-02-21",{"date":101,"type":42},"2024-12-18",{"date":103,"type":22},"2026-12",{"name":105,"class":49},"Hospital Sirio-Libanes",6]